Mineralys Therapeutics
Mr. Congleton has over thirty years of pharmaceutical experience including roles as CEO of both private and public companies. He has worked in cardiovascular, GI, respiratory and CNS companies with a focus on providing solutions for patients and their caregivers. He has raised over $175M in capital for the companies he has led as well launched and led the team behind market leading Copaxone in multiple sclerosis.
This person is not in any offices
Mineralys Therapeutics
2 followers
At Mineralys Therapeutics, they aim to redefine hypertension diagnosis, management, and treatment. They are driven to break the “trial and failure” approach to hypertension management and bring a personalized approach to the management of hypertension.